Mergers & Acquisitions ·
Biohaven licenses IgG degraders to Ono Pharma for $80M upfront and up to $100M in near-term payments
BHVNBiohaven Ltd.
Biohaven Ltd. entered into a Collaboration and License Agreement with Ono Pharmaceutical Co., Ltd. granting Ono an exclusive, royalty-bearing license to develop and commercialize Biohaven's MoDE pan IgG degrader portfolio, led by BHV-1300, in Japan, South Korea, Taiwan, and ASEAN countries. Under the terms of the agreement, Biohaven will receive a non-refundable upfront payment of $80 million upon closing and an additional $20 million milestone payment contingent on specified stability test results. Ono is responsible for development and commercialization costs in the licensed territory and will pay Biohaven royalties of approximately 20% on net sales. Biohaven retains all rights to the portfolio outside the licensed region, including in the United States, Europe, and China. The company operates as a biopharmaceutical firm focused on immunology, neuroscience, and oncology therapeutics.